The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples

Summary

Dabigatran is an oral direct thrombin inhibitor that does not require routine laboratory monitoring. However, an assessment of its anticoagulant effect in certain clinical settings is desirable. We examined the relationship between dabigatran levels, as determined by the Hemoclot thrombin inhibitor assay (HTI), the thrombin time (TT) and the activated partial thromboplastin time (aPTT) using different reagents. We describe these parameters with the clinical outcomes of patients receiving dabigatran. Seventy-five plasma samples from 47 patients were analysed. The HTI assay was established to measure dabigatran level. aPTTs were performed using TriniCLOT aPTT S reagent (TC) and three additional aPTT reagents. From linear regression lines, we established the aPTT ranges corresponding to the therapeutic drug levels for dabigatran (90–180 ng/ml). The aPTT demonstrated a modest correlation with the dabigatran level (r= 0.80) but the correlation became less reliable at higher dabigatran levels. The therapeutic aPTT ranges for reagents were clinically and statistically different compared with our reference reagent (46–54 s (TC) vs 51–60 s (SP), 54–64 s (SS) and 61–71 s (Actin FS) (p<0.05)). The TT was sensitive to the presence of dabigatran with a level of 60 ng/ml resulting in a TT > 300 s. In conclusion, the aPTT demonstrated a modest correlation with the dabigatran level and was less responsive with supra-therapeutic levels. aPTT reagents differed in their responsiveness, suggesting individual laboratories must determine their own therapeutic range for their aPTT reagent. The TT is too sensitive to quantify dabigatran levels, but a normal TT suggests minimal or no plasma dabigatran.

Keywords

Dabigatran - activated thromboplastin time (aPTT) - thrombin time (TT) - hemoclot thrombin inhibitor assay (HTI) - laboratory monitoring

• References

• 1 Connolly S, Ezekowitz M, Salim Y. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
• 2 Schulman S, Kearon C, Kakkar A. et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2341-2352.
• 3 Schulman S, Kearon C, Kakkar A. et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013; 368: 709-718.
• 4 Van Ryn J, Stangier J, Haertter S. et al. Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116-1127.
• 5 Blech S, Ebner T, Ludwig-Schwellinger E. et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metabol Disp 2008; 36: 386-399.
• 6 Therapeutic Goods Administration (homepage on the internet). Dabigatran (Pradaxa) and risk of bleeding: Information for health professionals. Updated 8 Feb 2013. Available at: http://www.tga.gov.au/safety/alerts-medicine-dabigatran-111005.htm Accessed April 11, 2013.
• 7 Harenberg J, Giese C, Marx S. et al. Determination of dabigatran in human plasma samples. Semin Thromb Hemost 2012; 38: 16-22.
• 8 Douxfils J, Mullier F, Robert S. et al. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 2012; 107: 985-997.
• 9 Lindahl T, Baghaei F, Blixter I. et al. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost 2011; 105: 371-378.
• 10 Halbmayer W, Weigel G, Quehenberger P. et al. Interference of the new oral anticoagulant dabigatran with frequently used coagulation tests. Clin Chem Lab Med 2012; 50: 1601-1605.
• 11 Dager W, Gosselin R, Kitchen S. et al. Dabigatran effects on the international normalised ratio, activated partial thromboplastin time, thrombin time, and fibrinogen: A multicentre, in vitro study. Ann Pharmacotherapy 2012; 46: 1627-1636.
• 12 Hyphen Biomed. Hemoclot Thrombin Inhibitor assay product insert..
• 13 Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinol 2012; 23: 138-143.
• 14 Avecilla S, Ferrell C, Chandler W. et al. Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy. Am J Clin Pathol 2012; 137: 572-574.
• 15 Ezekowitz M, Reilly P, Nehmiz G. et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol 2007; 100: 1419-1426.
• 16 Baglin T, Keeling D, Kitchen S. Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: Guidance from the British Committee for Standards in Haematology. Br J Haematol 2012; 159: 427-429.
• 17 Baglin T, Hillarp A, Tripodi A. et al. Measuring oral direct inhibitors (ODIs) of thrombin and factor Xa: A recommendation from the subcommittee on control of anticoagulation of the scientific and standardisation committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2013 Epub ahead of print.
• 18 Curvers J, van de Kerkhof D, Stroobants A. et al. Measuring direct thrombin inhibitors with routine and dedicated coagulation assays: which assay is helpful?. Am J Clin Pathol 2012; 138: 551-558.
• 19 Bonar R, Favaloro E, Marsden K. et al. Royal College Pathologists Australasia. New oral anticoagulants-questionnaire. Sydney: RCPA Quality Assurance Programs. October 2012